TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9036741

Group type: EXPERIMENTAL
Intervention: Heparin for ≤ 48 hours (group 1)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Heparin for > 48 hours (group 2)
Number of subjects: 450
Study: 1677818

Group type: EXPERIMENTAL
Intervention: Atracurium (0.3 mg/kg for <10 kg, 0.5 mg/kg for >10 kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vecuronium (0.05 mg/kg for <10 kg, 0.1 mg/kg for >10 kg)
Number of subjects: 40
Study: 7011037

Group type: EXPERIMENTAL
Intervention: Debridement and 3% acyclovir ointment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acyclovir alone
Number of subjects: 50
Study: 30689664

Group type: EXPERIMENTAL
Intervention: DRV/r + RAL
Number of subjects: 126
Study: 28903122

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (Q2W)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (Q4W)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 3
Study: 24251557

Group type: EXPERIMENTAL
Intervention: Weishi Bitong Xifang fumigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Voltaren emulgel
Number of subjects: 100
Study: 24793535

Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐34) (10, 20, 30, 40, 50, or 60 μg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multiple dose of rhPTH(1‐34) (10 and 20 μg once daily for 7 consecutive days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐34) (10, 20, or 40 μg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multiple dose of rhPTH(1‐34) (20 μg)
Number of subjects: 72
Study: 22551909

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d plus OAT with warfarin (C + OAT)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy with clopidogrel 75 mg/d plus aspirin 100 mg/d (C + ASA)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 341
Study: 19527382

Group type: EXPERIMENTAL
Intervention: External aortic compression device (EACD) with traditional management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional management alone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (traditional management)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: External aortic compression device (EACD)
Number of subjects: 300
Study: 17853393

Group type: EXPERIMENTAL
Intervention: FLOX (5-fluorouracil, leucovorin plus oxaliplatin)
Number of subjects: 1857

Group type: COMPARATOR
Intervention: FL (5-fluorouracil and leucovorin)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: FLOX
Number of subjects: 1857

Group type: COMPARATOR
Intervention: FL
Number of subjects: 1857
Study: 15457467

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice a day (n = 104)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo (n = 103)
Number of subjects: 207
Study: 11404671

Group type: EXPERIMENTAL
Intervention: ORAL (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON), no fluid trial
Number of subjects: 8
Study: 10791876

Group type: EXPERIMENTAL
Intervention: AIDSVAX (MN) vaccine (300 microg of MN-rgp120 in alum)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (alum)
Number of subjects: 33
Study: 7598995

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (BSN) for 8 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) for 8 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Amoxicillin (control group) for 4 weeks
Number of subjects: 66
Study: 2334624

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 50
Study: 306010

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (w.g.i.)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (w.g.i.) for removal of blood from the intestinal tract
Number of subjects: 163

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 163
Study: 31686817

Group type: EXPERIMENTAL
Intervention: Optimized DPX-loaded nanoparticles (30 mg single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed DPX tablet
Number of subjects: 0
Study: 29099839

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 751

Group type: COMPARATOR
Intervention: Condom use during first intercourse
Number of subjects: 751
Study: 25892169

Group type: EXPERIMENTAL
Intervention: 60-minute sessions of prolonged exposure (PE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 90-minute sessions of prolonged exposure (PE)
Number of subjects: 39
Study: 23398146

Group type: EXPERIMENTAL
Intervention: Multiplex Luminex bead assay for HNA allele detection
Number of subjects: 140
Study: 21553078

Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate, glycemic index (GI), glycemic load (GL)
Number of subjects: 30482
Study: 19609225

Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Red clover
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CEE/MPA
Number of subjects: 89
Study: 17597497

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise intervention (one hour per week for 12 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 47
Study: 15531304

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication (nonselective beta-blocker or prostaglandin analog)
Number of subjects: 689
Study: 11171592

Group type: EXPERIMENTAL
Intervention: 2%FAT
Number of subjects: 7

Group type: COMPARATOR
Intervention: 22%FAT
Number of subjects: 7
Study: 10093291

Group type: EXPERIMENTAL
Intervention: Bivalent Hib and hepatitis B vaccine (7.5 micrograms of PRP bound to 125 micrograms of OMP and 5 micrograms of recombinant hepatitis B surface antigen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent controls (Hib and hepatitis B)
Number of subjects: 0
Study: 9631980

Group type: EXPERIMENTAL
Intervention: benazepril 20 to 40 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: no benazepril
Number of subjects: 60
Study: 2667601

Group type: EXPERIMENTAL
Intervention: Spiramycin (3 X 10(6) iu, twice daily)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 5
Study: 770082

Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: 100 mg indomethacin per day
Number of subjects: 50
Study: 31286158

Group type: EXPERIMENTAL
Intervention: Electrotherapy, manual therapy, and pelvic floor muscle exercises
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64
Study: 28856399

Group type: EXPERIMENTAL
Intervention: 3D printing-assisted surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3D printing model (PLA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D imaging data
Number of subjects: 40
Study: 24941950

Group type: EXPERIMENTAL
Intervention: Volume-Based Feeding (VBF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rate-Based Feeding (RBF)
Number of subjects: 63
Study: 23294500

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice a day
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 21752899

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d for 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18997444

Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 17144779

Group type: EXPERIMENTAL
Intervention: Various strategies for minimizing NSAID risks including low dosages, modified-release and enteric-coated NSAIDs, cyclooxygenase-2-selective inhibitors, monitoring for side effects, and treatments to minimize side effects.
Number of subjects: 0
Study: 15165772

Group type: EXPERIMENTAL
Intervention: Radiofrequency sinus excision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Excision and marsupialization
Number of subjects: 30
Study: 12182036

Group type: EXPERIMENTAL
Intervention: 30 mCi
Number of subjects: 220

Group type: COMPARATOR
Intervention: 60 mCi
Number of subjects: 220
Study: 9231890

Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 120 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 180 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 240 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 0.5 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 2 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 8 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/120 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/180 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/240 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/120 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/180 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/240 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/120 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/180 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/240 mg
Number of subjects: 746

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Mono- and combination therapy
Number of subjects: 746
Study: 7965901

Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg once a day for 2 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluconazole plus chlorhexidine (chlorhexidine applied twice a day for 2 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: New dentures (no medication)
Number of subjects: 45
Study: 3283085

Group type: EXPERIMENTAL
Intervention: Mixed-beam radiotherapy (2 fractions a week of neutrons, 3 fractions a week of photons to a total RBE-adjusted dose of 50 Gy over 5 weeks plus intracavitary applications or external mixed-beam boost)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Photons only (50 Gy in 25 fractions over 5 weeks plus intracavitary applications or external-beam boost)
Number of subjects: 146
Study: 31310080

Group type: EXPERIMENTAL
Intervention: Intra-operative local mitomycin-C (MMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard vasovasostomy (Control)
Number of subjects: 40
Study: 29043411

Group type: EXPERIMENTAL
Intervention: T‐DM1 (ado-trastuzumab emtansine) administered weekly or every three weeks
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: T‐DM1 (ado-trastuzumab emtansine)
Number of subjects: 136
Study: 25345751

Group type: EXPERIMENTAL
Intervention: PtCr-EES
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation
Number of subjects: 100
Study: 22980443

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 439
Study: 21636241

Group type: EXPERIMENTAL
Intervention: Nonexpert feedback (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Expert feedback (Group C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 18
Study: 19486119

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 93

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 93
Study: 16843170

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) as an adjunct to primary percutaneous coronary intervention (PCI)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) alone
Number of subjects: 480
Study: 15931325

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors in postmenopausal women with invasive or intraductal breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxanes for patients with positive nodes and in the neoadjuvant setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted molecular therapies such as trastuzumab and bisphosphonates
Number of subjects: 0
Study: 10802838

Group type: EXPERIMENTAL
Intervention: Closed suction (Trach Care MAC)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Open suction
Number of subjects: 175
Study: 9355890

Group type: EXPERIMENTAL
Intervention: Physical exercise and low-fat diet (intervention group n=40)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 90
Study: 8320430

Group type: EXPERIMENTAL
Intervention: Thyroid function and volume monitoring during gestation in euthyroid pregnant women with excessive thyroidal stimulation.
Number of subjects: 0
Study: 2867985

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antiacids
Number of subjects: 20
Study: 29266633

Group type: EXPERIMENTAL
Intervention: Acupuncture/stretching plus physiotherapy (microwave diathermy and myofascial release)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Acupuncture/stretching
Number of subjects: 44
Study: 27003390

Group type: EXPERIMENTAL
Intervention: Behavioral activation program conducted weekly for 5 weeks in 60-min sessions
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Behavioral activation program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 25023786

Group type: EXPERIMENTAL
Intervention: WLC + PDD with hexaminolevulinate
Number of subjects: 151

Group type: COMPARATOR
Intervention: WLC alone (control)
Number of subjects: 151
Study: 22960764

Group type: EXPERIMENTAL
Intervention: Tofacitinib/basiliximab
Number of subjects: 15

Group type: COMPARATOR
Intervention: CNI/basiliximab
Number of subjects: 15

Group type: COMPARATOR
Intervention: CNI (tacrolimus)
Number of subjects: 15
Study: 19637333

Group type: EXPERIMENTAL
Intervention: EcN plus mesalamine (1500 mg twice a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 18362764

Group type: EXPERIMENTAL
Intervention: Errorless learning (EL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Self‐instruction training (SIT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 18
Study: 15849057

Group type: EXPERIMENTAL
Intervention: DTPa-IPV
Number of subjects: 416

Group type: COMPARATOR
Intervention: DTPa + IPV
Number of subjects: 416
Study: 12852099

Group type: EXPERIMENTAL
Intervention: Oral continuous‐combined regimen of conjugated estrogens + medroxyprogesterone acetate
Number of subjects: 0
Study: 10673888

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once daily for 4 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8598355

Group type: EXPERIMENTAL
Intervention: ERT + Mito (IV 12.5 mg/m(2) during the first and fourth week of ERT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: BCNU (i.v. 200 mg/m(2) every 6 weeks)
Number of subjects: 327

Group type: COMPARATOR
Intervention: 6-mercaptopurine (6-MP, 750 mg/m(2) IV daily for 3 days every six weeks)
Number of subjects: 327

Group type: COMPARATOR
Intervention: ERT alone (61.2 Gy)
Number of subjects: 327

Group type: COMPARATOR
Intervention: ERT + Mito
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Carmustine/6-MP
Number of subjects: 327
Study: 1927314

Group type: EXPERIMENTAL
Intervention: Laser ridge
Number of subjects: 271

Group type: COMPARATOR
Intervention: No laser ridge (Control)
Number of subjects: 271
Study: 6372066

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Trimipramine, 50 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study: 31046885

Group type: EXPERIMENTAL
Intervention: Machine learning accelerometer
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Standard cut-point accelerometer
Number of subjects: 333

Group type: COMPARATOR
Intervention: Cut-point accelerometer
Number of subjects: 333

Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 333
Study: 29023550

Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% BAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.00% BAC)
Number of subjects: 20
Study: 26522498

Group type: EXPERIMENTAL
Intervention: Problem-solving reminiscence activities
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Identity reminiscence activities
Number of subjects: 321

Group type: COMPARATOR
Intervention: Bitterness revival reminiscence activities
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control condition (any memory from their past)
Number of subjects: 321
Study: 25156987

Group type: EXPERIMENTAL
Intervention: Presence of depression (score ≥7 on the Short‐CARE depression scale)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Abnormal performance on executive function test and depression (n=57)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Abnormal performance on verbal recall test and depression (n=43)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Participants without depression
Number of subjects: 613
Study: 23092239

Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 18

Group type: COMPARATOR
Intervention: L. plantarum 299v
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli lozenges (L. reuteri DSM 17938 and ATCC PTA 5289)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test group (probiotic lozenges)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (placebo lozenges)
Number of subjects: 18
Study: 20804230

Group type: COMPARATOR
Intervention: Community health worker interventions
Number of subjects: 53
Study: 17240231

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg vaginally
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 200
Study: 15701249

Group type: EXPERIMENTAL
Intervention: Paromomycin ointment (15%) applied twice daily for 30 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (10% urea lotion) applied twice daily for 30 days
Number of subjects: 65
Study: 12088953

Group type: EXPERIMENTAL
Intervention: Ketamine (1.0 mg/kg) with propofol and fentanyl (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ketamine (Group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group A (Ketamine)
Number of subjects: 70
Study: 10489823

Group type: EXPERIMENTAL
Intervention: Acetaldehyde
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Log PC20,acet/PC20,meth
Number of subjects: 26
Study: 8951252

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) after surfactant administration (100 mg/kg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 125
Study: 2024598

Group type: EXPERIMENTAL
Intervention: 8-week program of exercise conditioning and behavioral counseling
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 201
Study: 6164480

Group type: EXPERIMENTAL
Intervention: Actinomycin D (AMD) and Vincristine (VCR) for 6 or 15 months (Group I)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Actinomycin D (AMD) and Vincristine (VCR) plus Adriamycin (Reg. D) for 15 months (Groups II and III)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Actinomycin D (AMD) and Vincristine (VCR) (Reg. C) for 15 months (Groups II and III)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Unfavorable histology (UH)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Favorable histology (FH)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Positive lymph nodes
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Negative lymph nodes
Number of subjects: 188
Study: 31521157

Group type: EXPERIMENTAL
Intervention: HIV counseling and testing (HTC) performed in family planning clinics
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Clinics with trained HIV testing providers
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Public clinics versus non-public clinics
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Having an HIV comprehensive care center (CCC) onsite
Number of subjects: 4389
Study: 27777261

Group type: EXPERIMENTAL
Intervention: Exenatide infusion (n=29)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Liraglutide (n=19)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%; n=28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Matching placebo (n=17)
Number of subjects: 57
Study: 26061837

Group type: EXPERIMENTAL
Intervention: Enhanced Assess, Acknowledge, Act Sexual Assault Resistance program (resistance group)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Access to brochures on sexual assault (control group)
Number of subjects: 893
Study: 22607455

Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 67
Study: 21740575

Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption (≥3000 kJ before 1100 each day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Extended fasting (abstaining from energy-providing nutrients until 1200 each day)
Number of subjects: 70
Study: 19214934

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16927570

Group type: EXPERIMENTAL
Intervention: Child Behaviour Checklist/CBCL 1 1/2‐5
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Parent Rating Scale for Attention‐Deficit Hyperactivity Disorder (ADHD)
Number of subjects: 280